Welcome Cure raises Half a million $ in Pre-series A Round led by Inflection Point Ventures in its on-going Funding Round

▴ Welcome Cure
Welcome Cure is a fully integrated Homeopathy Technology company that offers Assisted intelligence (AI)-powered solutions for doctors and patients, ensuring both effective prescriptions and convenient access to healthcare regardless of location. The funds will be utilized for growth, including talent acquisition, technology enhancement and marketing initiatives. Inflection Point Ventures (IPV) has so far invested over INR 600 Cr across 190+ deals.

Mumbai,October 19, 2023, : Welcome Cure has raised over 4 Crores in Pre-series A Round led by Inflection Point Ventures (IPV). The funds will be utilized for growth, including talent acquisition, technology enhancement, and marketing initiatives. IPV has led the round and Welcome Cure is looking at raising over 16 crores in this on-going funding round.

Welcome Cure addresses the growing demand for sustainable and holistic healthcare by providing a comprehensive one-stop solution in the fragmented homeopathy market, offering convenient online and offline services for diagnosis, treatment, and monitoring, with a focus on prevention and overall well-being.

Welcome Cure is led by a team of experienced and accomplished individuals. Dr. Jawahar Shah, the Founder, brings 45 years of clinical practice as an MD in Homeopathy and holds a post-graduate degree from London. Punit Desai, the Co-founder, and CEO, contributes his expertise with an MBA and over 10 years of entrepreneurship experience. Nidhi Desai, the Co-founder, and COO, also brings an MBA and over 10 years of entrepreneurship experience to the team. Together, they form a strong leadership that drives Welcome Cure's mission to provide holistic healthcare solutions through their innovative platform.

Vikram Ramasubramanian, Partner, Inflection Point Ventures, says, “While Homeopathy treatment is well recognised across the globe, the number of people opting for such treatment is also growing exponentially. The main reason for such acceptance is the ability to provide treatment to the root cause, especially chronic disease which is recurring and needs utmost attention. Welcomecure with its unique healthcare solution has been able to offer its patients the much-needed treatment regardless of location. The brand itself has grown multifolds with its ability to offer seamless interaction between its patients and doctors, onboard best   caregivers and experts in homeopathic medicine and providing a holistic solution all under a roof. We at IPV look forward to scaling their new age business with strategic guidance and enable the brand to benefit more and more individuals”.

Welcome Cure operates at an impressive scale, with 2.5 million platform users and 1.5 million+ registered patients in 36+ countries. Their software business serves over 1 lakh doctors in 140+ countries.

Welcome Cure stands out in the healthcare industry with its modernized homeopathy and holistic care solutions, catering to patients' needs in a comprehensive manner. Their unique proposition lies in the integration of proprietary Assisted Intelligence (AI) solutions, which serve as a valuable decision support system for physicians. This AI-powered technology enhances diagnostic accuracy, treatment selection, and monitoring, ensuring optimal patient care. Welcome Cure's commitment to an integrated and 360-degree technology-powered solution further solidifies their position as leaders in the homeopathy domain.

Dr. Jawahar Shah, Founder, Welcome Cure says, “Homeopathy has been around for more than 200 years, grown consistently and served humanity. It enjoys acceptance from all socio-economic classes and has a wide presence across the world. As per WHO it is the 2nd largest system of medicine and used in over 100 countries. In a $9 Billion+ market there is immense potential as it's growing at over 18% CAGR and there is a missing brand which is a name synonym to Homeopathy. Welcome Cure desires to do that and be that. Emerge as the 1st choice when anyone thinks of Homeopathy Care. With IPVs participation in Welcome Cure as an equity and growth investor we are poised to make this vision come to light.”

 

Welcome Cure has achieved remarkable organic growth since its inception, with a positive return for the past two years. Within the last couple of years alone, the company has achieved a cumulative business of over 45+ crores, demonstrating its strong presence in the Alternative Medicine space. The startup and its founders have also received recognition and accolades from esteemed institutions and bodies, including testimonials and awards from Prime Minister Narendra Modi, the Ministry of Electronics & IT, and other prestigious organizations.

The Homeopathy industry is currently valued at over 7 billion USD and is experiencing a growth rate of 18% CAGR (Compound Annual Growth Rate). Projections indicate that the industry is expected to surpass 21 billion USD within the next 5 to 7 years, indicating significant growth potential in the near future.

About Welcome Cure

Welcome Cure is a fully integrated Homeopathy Technology company with a proprietary Assisted Intelligence (AI) powered solution for doctors. The brand also serves patients across the globe with holistic care solutions via its Tele-medicine Platform. The start-up has served 2.5 million + Patients in 36+ countries via its proprietary Tele-medicine platform. The software business division has catered to over 100K+ doctors in 140+ countries with mobile applications and decision support system software

About Inflection Point Ventures & Physis Capital

Inflection Point Ventures (IPV) is an angel investing platform with over 8600 CXOs, HNIs, and Professionals to together invest in startups. The firm supports new-age entrepreneurs by providing them with monetary & experiential capital and connecting them with a diverse group of investors. IPV has announced the launch of a $50 million CAT 2 AIF Physis Capital to invest in pre-Series A to Series B growth-stage start-ups.

Tags : #welcomecure #seriesA #funding #IPV #homeopathy #AI #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Role of Genetic Profiles in Alzheimer’s Therapy: APOE4 and Treatment ResponsesMay 08, 2024
Assessing Covishield Safety: Indian Research Offers Reassurance Amidst Rare Side Effect DiscussionsMay 08, 2024
Quadria Capital Invests $102 Million in NephroPlus to Boost Dialysis Services Across AsiaMay 08, 2024
When Your Body Makes Beer: Exploring the Curious Case of Auto-Brewery SyndromeMay 07, 2024
Hair Today, Gone Tomorrow: Why Guys Go Bald Before Marriage May 07, 2024
Menopausal Transitions and Mental Health: UCL Study Highlights Increased Depression RiskMay 07, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Harnessing AI for Early Alzheimer's Disease Diagnosis: IIT Indore's BreakthroughMay 06, 2024
Aurobindo Pharma's Bhiwadi Facility Under FDA Scrutiny: Understanding the ObservationsMay 06, 2024
Exploring the Role of Mediator Protein Complex in Cell Division: Implications for Disease ManagementMay 06, 2024
Akshay Tritiya Parna Mahotsav is to be held in the cityMay 04, 2024
Bharti Singh's Battle with Gallstones: Symptoms, Precautions, and Natural RemediesMay 04, 2024
Empowering Women's Health: New Mammogram GuidelinesMay 04, 2024
Rising Temperatures, Rising Risks: Addressing the Challenges of Heat StressMay 04, 2024
Gynoveda, India's First Ayurveda Fertility Company, Expands Reach with New Clinic in Pune, Set to Open 100 Clinics Across India by 2027May 03, 2024
Aptus Value Housing Finance India Limited, a leading Housing Finance Company has declared its financial results for the year ended March 31, 2024. FY 24 ResultsMay 03, 2024
TIPS FOR PREGNANCY CARE DURING SUMMERMay 03, 2024
The deadly intersection: TB and tobacco smoking co-epidemics in Indonesia Dr TARA SINGH BAM – CNSMay 03, 2024
Mintoak Expands Global Footprint with Strategic Leadership AppointmentsMay 03, 2024